A Profitable Robotic-Surgery Compounder With ~39% Upside — And One Catch
Record non-GAAP profits, raised guidance, a sticky robotic-implant moat, 95% institutional ownership, and ~39% upside to target. The catch isn't the price — it's the cooling top line. Here's the honest setup.